GlassScriptPhysician profile
Adil Karamali
NPI 1811998297
$8,684.43
in general payments reported to CMS, 2019-2025
26 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,076 · 2020: $845 · 2021: $541 · 2022: $550 · 2023: $510 · 2024: $674 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,539.61 | 2019 | |
| Cardiovascular Systems INC. | $1,331.49 | 2019-2021 | |
| Ekos Corporation | $720.27 | 2019 | |
| Pfizer INC. | $717.62 | 2019-2025 | |
| Biotronik INC. | $599.48 | 2019 | |
| Abiomed | $584.13 | 2019-2020 | |
| Boston Scientific Corporation | $581.15 | 2020-2025 | Watchman Flx, Avvigo Guidance System, Watchman Access System |
| Abbott Laboratories | $422.51 | 2021-2025 | Ultreon, Coroflow, Optis |
| Inari Medical, INC. | $400.20 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $383.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $329.31 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $217.25 | 2023-2025 | |
| United Therapeutics Corporation | $122.32 | 2020 | |
| Janssen Pharmaceuticals, INC | $106.26 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $105.94 | 2019-2025 | Wainua |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.45 | 2019-2025 | Lifevest |
| Astellas Pharma US INC | $94.11 | 2020 | |
| Medtronic, INC. | $89.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.42 | 2020-2025 | Jardiance |
| Amgen INC. | $49.69 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $39.73 | 2024-2025 | Verquvo |
| Chiesi USA, INC. | $23.00 | 2023 | Kengreal, Cleviprex |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2019 | |
| Novo Nordisk INC | $17.83 | 2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $15.79 | 2020 | |
| Philips North America LLC | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Karamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.